Literature DB >> 9097417

Epitope regions in the heavy chain of Clostridium botulinum type E neurotoxin recognized by monoclonal antibodies.

T Kubota1, T Watanabe, N Yokosawa, K Tsuzuki, T Indoh, K Moriishi, K Sanda, Y Maki, K Inoue, N Fujii.   

Abstract

Seventeen monoclonal antibodies (MAbs) were previously established against the heavy chain (Hc) of botulinum type E neurotoxin in BALB/c mice immunized with the type E toxoid. Five MAbs (LE15-5, LE34-6, EK19-7, EK21-4, and AE27-9) showed toxin-neutralizing activity in mice. Two of the five MAbs, EK19-7 and EK21-4, recognized the regions located at amino acid positions 731 to 787 and 811 to 897, respectively. One of the remaining three antibodies (LE34-6) reacted with the amino acid sequence VIKAIN, at amino acid positions 663 to 668, closed by the ion channel-forming domain. It is suggested that the ion channel-forming domain may also be associated with the blocking of acetylcholine release. Furthermore, the amino acid sequence YLTHMRD within 30 residues of the C-terminal region of the Hc component seemed to be recognized by LE15-5. It has been reported that the binding domain of the type E toxin is located on the C-terminal half of the Hc component. Therefore, the neutralizing activity of LE15-5 antibody may be attributed to its ability to block the binding of neurotoxin to the receptor of target cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9097417      PMCID: PMC168414          DOI: 10.1128/aem.63.4.1214-1218.1997

Source DB:  PubMed          Journal:  Appl Environ Microbiol        ISSN: 0099-2240            Impact factor:   4.792


  17 in total

1.  Identification of an ion channel-forming motif in the primary structure of tetanus and botulinum neurotoxins.

Authors:  M S Montal; R Blewitt; J M Tomich; M Montal
Journal:  FEBS Lett       Date:  1992-11-16       Impact factor: 4.124

2.  Activation of Clostridium botulinum type E toxin purified by two different procedures.

Authors:  N Yokosawa; K Tsuzuki; B Syuto; K Oguma
Journal:  J Gen Microbiol       Date:  1986-07

3.  Peptide mapping by limited proteolysis in sodium dodecyl sulfate and analysis by gel electrophoresis.

Authors:  D W Cleveland; S G Fischer; M W Kirschner; U K Laemmli
Journal:  J Biol Chem       Date:  1977-02-10       Impact factor: 5.157

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Proteolysis of SNAP-25 by types E and A botulinal neurotoxins.

Authors:  T Binz; J Blasi; S Yamasaki; A Baumeister; E Link; T C Südhof; R Jahn; H Niemann
Journal:  J Biol Chem       Date:  1994-01-21       Impact factor: 5.157

6.  Botulinum neurotoxin type G proteolyses the Ala81-Ala82 bond of rat synaptobrevin 2.

Authors:  S Yamasaki; T Binz; T Hayashi; E Szabo; N Yamasaki; M Eklund; R Jahn; H Niemann
Journal:  Biochem Biophys Res Commun       Date:  1994-04-29       Impact factor: 3.575

7.  Purification and characterization of the ganglioside-binding fragment of Clostridium botulinum type E neurotoxin.

Authors:  Y Kamata; Y Kimura; T Hiroi; G Sakaguchi; S Kozaki
Journal:  Biochim Biophys Acta       Date:  1993-02-13

8.  Botulinum neurotoxin C1 blocks neurotransmitter release by means of cleaving HPC-1/syntaxin.

Authors:  J Blasi; E R Chapman; S Yamasaki; T Binz; H Niemann; R Jahn
Journal:  EMBO J       Date:  1993-12       Impact factor: 11.598

9.  Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP/synaptobrevin.

Authors:  G Schiavo; C C Shone; O Rossetto; F C Alexander; C Montecucco
Journal:  J Biol Chem       Date:  1993-06-05       Impact factor: 5.157

10.  Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin.

Authors:  G Schiavo; F Benfenati; B Poulain; O Rossetto; P Polverino de Laureto; B R DasGupta; C Montecucco
Journal:  Nature       Date:  1992-10-29       Impact factor: 49.962

View more
  14 in total

1.  High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A.

Authors:  D D Pless; E R Torres; E K Reinke; S Bavari
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

Review 2.  Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia.

Authors:  David P Figgitt; Stuart Noble
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Evaluation of chemical degradation of a trivalent recombinant protein vaccine against botulinum neurotoxin by LysC peptide mapping and MALDI-TOF mass spectrometry.

Authors:  Tia Estey; Christina Vessely; Theodore W Randolph; Ian Henderson; Latoya Jones Braun; Rajiv Nayar; John F Carpenter
Journal:  J Pharm Sci       Date:  2009-09       Impact factor: 3.534

4.  Subunit vaccine against the seven serotypes of botulism.

Authors:  Michael R Baldwin; William H Tepp; Amanda Przedpelski; Christina L Pier; Marite Bradshaw; Eric A Johnson; Joseph T Barbieri
Journal:  Infect Immun       Date:  2007-12-10       Impact factor: 3.441

5.  Sequencing the botulinum neurotoxin gene and related genes in Clostridium botulinum type E strains reveals orfx3 and a novel type E neurotoxin subtype.

Authors:  Ying Chen; Hannu Korkeala; Johannes Aarnikunnas; Miia Lindström
Journal:  J Bacteriol       Date:  2007-09-28       Impact factor: 3.490

6.  Comparative study of immunological and structural properties of two recombinant vaccine candidates against botulinum neurotoxin type E.

Authors:  Mosayeb Rostamian; Seyed Jafar Mousavy; Firouz Ebrahimi; Seyyed Abolghasem Ghadami; Nader Sheibani; Mohammad Ebrahim Minaei; Mohammad Ali Arefpour Torabi
Journal:  Iran Biomed J       Date:  2012

Review 7.  Analysis of epitope information related to Bacillus anthracis and Clostridium botulinum.

Authors:  Laura M Zarebski; Kerrie Vaughan; John Sidney; Bjoern Peters; Howard Grey; Kim D Janda; Arturo Casadevall; Alessandro Sette
Journal:  Expert Rev Vaccines       Date:  2008-02       Impact factor: 5.217

Review 8.  Emerging opportunities for serotypes of botulinum neurotoxins.

Authors:  Zhongxing Peng Chen; J Glenn Morris; Ramon L Rodriguez; Aparna Wagle Shukla; John Tapia-Núñez; Michael S Okun
Journal:  Toxins (Basel)       Date:  2012-11-07       Impact factor: 4.546

9.  Mapping of the antibody-binding regions on the HN-domain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the H-chain of botulinum neurotoxin A.

Authors:  M Zouhair Atassi; Behzod Z Dolimbek
Journal:  Protein J       Date:  2004-01       Impact factor: 4.000

10.  Development of Human-Like scFv-Fc Neutralizing Botulinum Neurotoxin E.

Authors:  Sebastian Miethe; Christine Rasetti-Escargueil; Arnaud Avril; Yvonne Liu; Siham Chahboun; Hannu Korkeala; Christelle Mazuet; Michel-Robert Popoff; Thibaut Pelat; Philippe Thullier; Dorothea Sesardic; Michael Hust
Journal:  PLoS One       Date:  2015-10-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.